BACE1 and Alzheimer disease: BACE1 inhibitors are recognized as potential candidates for disease-modifying AD drugs, but their development has been unsatisfactory to date, due to difficulties identifying compounds with desired effects in the central nervous system (CNS), especially due to difficulties in achieving blood-brain barrier penetration [5], [9].